#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=3. TRP Channels in Colorectal Cancers
1-1	0-2	3.	_	_	_	_
1-2	3-6	TRP	abstract|abstract[2]	new|new[2]	coref|coref	5-16|5-15[33_2]
1-3	7-15	Channels	abstract[2]	new[2]	_	_
1-4	16-18	in	abstract[2]	new[2]	_	_
1-5	19-29	Colorectal	abstract[2]|abstract[3]	new[2]|new[3]	coref	7-12[54_3]
1-6	30-37	Cancers	abstract[2]|abstract[3]	new[2]|new[3]	_	_

#Text=Colorectal cancer ( CRC ) , the most prevalent cancer of the GI tract , represents the third most commonly diagnosed malignancy worldwide in men and women and the second largest cause of death in Europe related to cancer .
2-1	38-48	Colorectal	place|abstract[5]	new|new[5]	appos	2-4[0_5]
2-2	49-55	cancer	abstract[5]	new[5]	_	_
2-3	56-57	(	_	_	_	_
2-4	58-61	CRC	abstract	giv	appos	2-7[7_0]
2-5	62-63	)	_	_	_	_
2-6	64-65	,	_	_	_	_
2-7	66-69	the	abstract[7]	giv[7]	coref	2-39[0_7]
2-8	70-74	most	abstract[7]	giv[7]	_	_
2-9	75-84	prevalent	abstract[7]	giv[7]	_	_
2-10	85-91	cancer	abstract[7]	giv[7]	_	_
2-11	92-94	of	abstract[7]	giv[7]	_	_
2-12	95-98	the	abstract[7]|object[9]	giv[7]|new[9]	_	_
2-13	99-101	GI	abstract[7]|abstract|object[9]	giv[7]|new|new[9]	_	_
2-14	102-107	tract	abstract[7]|object[9]	giv[7]|new[9]	_	_
2-15	108-109	,	_	_	_	_
2-16	110-120	represents	_	_	_	_
2-17	121-124	the	abstract[10]	new[10]	_	_
2-18	125-130	third	abstract[10]	new[10]	_	_
2-19	131-135	most	abstract[10]	new[10]	_	_
2-20	136-144	commonly	abstract[10]	new[10]	_	_
2-21	145-154	diagnosed	abstract[10]	new[10]	_	_
2-22	155-165	malignancy	abstract[10]	new[10]	_	_
2-23	166-175	worldwide	abstract[10]	new[10]	_	_
2-24	176-178	in	_	_	_	_
2-25	179-182	men	person	new	_	_
2-26	183-186	and	_	_	_	_
2-27	187-192	women	person	new	_	_
2-28	193-196	and	_	_	_	_
2-29	197-200	the	abstract[13]	new[13]	_	_
2-30	201-207	second	abstract[13]	new[13]	_	_
2-31	208-215	largest	abstract[13]	new[13]	_	_
2-32	216-221	cause	abstract[13]	new[13]	_	_
2-33	222-224	of	abstract[13]	new[13]	_	_
2-34	225-230	death	abstract[13]|person[14]	new[13]|new[14]	coref	8-36[77_14]
2-35	231-233	in	abstract[13]|person[14]	new[13]|new[14]	_	_
2-36	234-240	Europe	abstract[13]|person[14]|place	new[13]|new[14]|new	_	_
2-37	241-248	related	abstract[13]	new[13]	_	_
2-38	249-251	to	abstract[13]	new[13]	_	_
2-39	252-258	cancer	abstract[13]|abstract	new[13]|giv	coref	3-19
2-40	259-260	.	_	_	_	_

#Text=Growth factors , oncogenes and receptors play a critical role in the tumorigenesis , and the propagation of CRC .
3-1	261-267	Growth	abstract[17]	new[17]	coref	4-3[24_17]
3-2	268-275	factors	abstract[17]	new[17]	_	_
3-3	276-277	,	_	_	_	_
3-4	278-287	oncogenes	substance	new	_	_
3-5	288-291	and	_	_	_	_
3-6	292-301	receptors	substance	new	_	_
3-7	302-306	play	_	_	_	_
3-8	307-308	a	abstract[20]	new[20]	coref	7-23[55_20]
3-9	309-317	critical	abstract[20]	new[20]	_	_
3-10	318-322	role	abstract[20]	new[20]	_	_
3-11	323-325	in	abstract[20]	new[20]	_	_
3-12	326-329	the	abstract[20]|abstract[21]	new[20]|new[21]	coref	11-11[92_21]
3-13	330-343	tumorigenesis	abstract[20]|abstract[21]	new[20]|new[21]	_	_
3-14	344-345	,	abstract[20]	new[20]	_	_
3-15	346-349	and	abstract[20]	new[20]	_	_
3-16	350-353	the	abstract[20]|event[22]	new[20]|new[22]	_	_
3-17	354-365	propagation	abstract[20]|event[22]	new[20]|new[22]	_	_
3-18	366-368	of	abstract[20]|event[22]	new[20]|new[22]	_	_
3-19	369-372	CRC	abstract[20]|event[22]|abstract	new[20]|new[22]|giv	coref	4-15
3-20	373-374	.	_	_	_	_

#Text=However , other environmental and genetic factors play significant roles in the development of CRC .
4-1	375-382	However	_	_	_	_
4-2	383-384	,	_	_	_	_
4-3	385-390	other	abstract[24]	giv[24]	_	_
4-4	391-404	environmental	abstract[24]	giv[24]	_	_
4-5	405-408	and	abstract[24]	giv[24]	_	_
4-6	409-416	genetic	abstract[24]	giv[24]	_	_
4-7	417-424	factors	abstract[24]	giv[24]	_	_
4-8	425-429	play	_	_	_	_
4-9	430-441	significant	abstract[25]	new[25]	_	_
4-10	442-447	roles	abstract[25]	new[25]	_	_
4-11	448-450	in	abstract[25]	new[25]	_	_
4-12	451-454	the	abstract[25]|event[26]	new[25]|new[26]	_	_
4-13	455-466	development	abstract[25]|event[26]	new[25]|new[26]	_	_
4-14	467-469	of	abstract[25]|event[26]	new[25]|new[26]	_	_
4-15	470-473	CRC	abstract[25]|event[26]|abstract	new[25]|new[26]|giv	coref	5-25
4-16	474-475	.	_	_	_	_

#Text=Over the last two decades , accumulating evidence has demonstrated that several members of the TRP family channels show altered expression and activity in cancer cells .
5-1	476-480	Over	_	_	_	_
5-2	481-484	the	time[28]	new[28]	_	_
5-3	485-489	last	time[28]	new[28]	_	_
5-4	490-493	two	time[28]	new[28]	_	_
5-5	494-501	decades	time[28]	new[28]	_	_
5-6	502-503	,	_	_	_	_
5-7	504-516	accumulating	abstract[29]	new[29]	_	_
5-8	517-525	evidence	abstract[29]	new[29]	_	_
5-9	526-529	has	_	_	_	_
5-10	530-542	demonstrated	_	_	_	_
5-11	543-547	that	_	_	_	_
5-12	548-555	several	animal[30]	new[30]	_	_
5-13	556-563	members	animal[30]	new[30]	_	_
5-14	564-566	of	animal[30]	new[30]	_	_
5-15	567-570	the	animal[30]|abstract[33]	new[30]|giv[33]	coref	14-15[127_33]
5-16	571-574	TRP	animal[30]|abstract|organization[32]|abstract[33]	new[30]|giv|new[32]|giv[33]	coref	14-17
5-17	575-581	family	animal[30]|organization[32]|abstract[33]	new[30]|new[32]|giv[33]	_	_
5-18	582-590	channels	animal[30]|abstract[33]	new[30]|giv[33]	_	_
5-19	591-595	show	_	_	_	_
5-20	596-603	altered	abstract[34]|abstract[35]	new[34]|new[35]	coref|coref	6-3[40_34]|11-22[98_35]
5-21	604-614	expression	abstract[34]|abstract[35]	new[34]|new[35]	_	_
5-22	615-618	and	abstract[35]	new[35]	_	_
5-23	619-627	activity	abstract[35]|abstract	new[35]|new	coref	8-1[61_0]
5-24	628-630	in	_	_	_	_
5-25	631-637	cancer	abstract|object[38]	giv|new[38]	coref|coref	6-15|12-19[111_38]
5-26	638-643	cells	object[38]	new[38]	_	_
5-27	644-645	.	_	_	_	_

#Text=Levels of expression of TRPC , TRPM , and TRPV proteins depend on the cancer stage .
6-1	646-652	Levels	abstract[39]	new[39]	_	_
6-2	653-655	of	abstract[39]	new[39]	_	_
6-3	656-666	expression	abstract[39]|abstract[40]	new[39]|giv[40]	coref	11-22[97_40]
6-4	667-669	of	abstract[39]|abstract[40]	new[39]|giv[40]	_	_
6-5	670-674	TRPC	abstract[39]|abstract[40]|abstract|substance[44]	new[39]|giv[40]|new|new[44]	_	_
6-6	675-676	,	abstract[39]|abstract[40]|substance[44]	new[39]|giv[40]|new[44]	_	_
6-7	677-681	TRPM	abstract[39]|abstract[40]|abstract|substance[44]	new[39]|giv[40]|new|new[44]	_	_
6-8	682-683	,	abstract[39]|abstract[40]|substance[44]	new[39]|giv[40]|new[44]	_	_
6-9	684-687	and	abstract[39]|abstract[40]|substance[44]	new[39]|giv[40]|new[44]	_	_
6-10	688-692	TRPV	abstract[39]|abstract[40]|abstract|substance[44]	new[39]|giv[40]|new|new[44]	_	_
6-11	693-701	proteins	abstract[39]|abstract[40]|substance[44]	new[39]|giv[40]|new[44]	_	_
6-12	702-708	depend	_	_	_	_
6-13	709-711	on	_	_	_	_
6-14	712-715	the	abstract[46]	new[46]	_	_
6-15	716-722	cancer	abstract|abstract[46]	giv|new[46]	coref	8-7
6-16	723-728	stage	abstract[46]	new[46]	_	_
6-17	729-730	.	_	_	_	_

#Text=Those differences have been recognized mainly in melanoma , glioma and prostate , breast , kidney , and bladder cancers , suggesting an oncogenic role for some TRPs while others may function as tumor suppressors .
7-1	731-736	Those	abstract[47]	new[47]	coref	14-28[131_47]
7-2	737-748	differences	abstract[47]	new[47]	_	_
7-3	749-753	have	_	_	_	_
7-4	754-758	been	_	_	_	_
7-5	759-769	recognized	_	_	_	_
7-6	770-776	mainly	_	_	_	_
7-7	777-779	in	_	_	_	_
7-8	780-788	melanoma	abstract	new	_	_
7-9	789-790	,	_	_	_	_
7-10	791-797	glioma	abstract	new	_	_
7-11	798-801	and	_	_	_	_
7-12	802-810	prostate	object|abstract[54]	new|giv[54]	coref	16-27
7-13	811-812	,	abstract[54]	giv[54]	_	_
7-14	813-819	breast	place|abstract[54]	new|giv[54]	_	_
7-15	820-821	,	abstract[54]	giv[54]	_	_
7-16	822-828	kidney	object|abstract[54]	new|giv[54]	_	_
7-17	829-830	,	abstract[54]	giv[54]	_	_
7-18	831-834	and	abstract[54]	giv[54]	_	_
7-19	835-842	bladder	object|abstract[54]	new|giv[54]	_	_
7-20	843-850	cancers	abstract[54]	giv[54]	_	_
7-21	851-852	,	_	_	_	_
7-22	853-863	suggesting	_	_	_	_
7-23	864-866	an	abstract[55]	giv[55]	coref	11-5[90_55]
7-24	867-876	oncogenic	abstract[55]	giv[55]	_	_
7-25	877-881	role	abstract[55]	giv[55]	_	_
7-26	882-885	for	abstract[55]	giv[55]	_	_
7-27	886-890	some	abstract[55]|abstract[56]	giv[55]|new[56]	coref	15-22[143_56]
7-28	891-895	TRPs	abstract[55]|abstract[56]	giv[55]|new[56]	_	_
7-29	896-901	while	_	_	_	_
7-30	902-908	others	person	new	_	_
7-31	909-912	may	_	_	_	_
7-32	913-921	function	_	_	_	_
7-33	922-924	as	_	_	_	_
7-34	925-930	tumor	abstract|abstract[59]	new|new[59]	coref	8-18
7-35	931-942	suppressors	abstract[59]	new[59]	_	_
7-36	943-944	.	_	_	_	_

#Text=TRPs activity implicates many aspects of cancer development or “ hallmarks of cancer ” , such as tumor migration and invasion , exaggerated cell proliferation , cell survival , angiogenesis , and enhanced resistance to cell death .
8-1	945-949	TRPs	abstract|abstract[61]	new|giv[61]	_	_
8-2	950-958	activity	abstract[61]	giv[61]	_	_
8-3	959-969	implicates	_	_	_	_
8-4	970-974	many	abstract[62]	new[62]	_	_
8-5	975-982	aspects	abstract[62]	new[62]	_	_
8-6	983-985	of	abstract[62]	new[62]	_	_
8-7	986-992	cancer	abstract[62]|abstract|event[64]	new[62]|giv|new[64]	coref	8-13
8-8	993-1004	development	abstract[62]|event[64]	new[62]|new[64]	_	_
8-9	1005-1007	or	abstract[62]	new[62]	_	_
8-10	1008-1009	“	abstract[62]	new[62]	_	_
8-11	1010-1019	hallmarks	abstract[62]|abstract[65]	new[62]|new[65]	_	_
8-12	1020-1022	of	abstract[62]|abstract[65]	new[62]|new[65]	_	_
8-13	1023-1029	cancer	abstract[62]|abstract[65]|abstract	new[62]|new[65]|giv	coref	9-14
8-14	1030-1031	”	abstract[62]	new[62]	_	_
8-15	1032-1033	,	abstract[62]	new[62]	_	_
8-16	1034-1038	such	abstract[62]	new[62]	_	_
8-17	1039-1041	as	abstract[62]	new[62]	_	_
8-18	1042-1047	tumor	abstract[62]|abstract|abstract[68]	new[62]|giv|new[68]	coref	15-33
8-19	1048-1057	migration	abstract[62]|abstract[68]	new[62]|new[68]	_	_
8-20	1058-1061	and	abstract[62]	new[62]	_	_
8-21	1062-1070	invasion	abstract[62]|event	new[62]|new	_	_
8-22	1071-1072	,	abstract[62]	new[62]	_	_
8-23	1073-1084	exaggerated	abstract[62]|abstract[71]	new[62]|new[71]	coref	13-23[120_71]
8-24	1085-1089	cell	abstract[62]|place|abstract[71]	new[62]|new|new[71]	coref	8-27
8-25	1090-1103	proliferation	abstract[62]|abstract[71]	new[62]|new[71]	_	_
8-26	1104-1105	,	abstract[62]	new[62]	_	_
8-27	1106-1110	cell	abstract[62]|place|event[73]	new[62]|giv|new[73]	coref	8-36
8-28	1111-1119	survival	abstract[62]|event[73]	new[62]|new[73]	_	_
8-29	1120-1121	,	abstract[62]	new[62]	_	_
8-30	1122-1134	angiogenesis	abstract[62]|abstract	new[62]|new	_	_
8-31	1135-1136	,	abstract[62]	new[62]	_	_
8-32	1137-1140	and	abstract[62]	new[62]	_	_
8-33	1141-1149	enhanced	abstract[62]|abstract[75]	new[62]|new[75]	_	_
8-34	1150-1160	resistance	abstract[62]|abstract[75]	new[62]|new[75]	_	_
8-35	1161-1163	to	abstract[62]|abstract[75]	new[62]|new[75]	_	_
8-36	1164-1168	cell	abstract[62]|abstract[75]|place|person[77]	new[62]|new[75]|giv|giv[77]	coref	13-14
8-37	1169-1174	death	abstract[62]|abstract[75]|person[77]	new[62]|new[75]|giv[77]	_	_
8-38	1175-1176	.	_	_	_	_

#Text=To date , TRPV1 and TRPV6 have been exclusively recognized as relevant in CRC carcinogenesis .
9-1	1177-1179	To	_	_	_	_
9-2	1180-1184	date	time	new	_	_
9-3	1185-1186	,	_	_	_	_
9-4	1187-1192	TRPV1	abstract	new	coref	10-6
9-5	1193-1196	and	_	_	_	_
9-6	1197-1202	TRPV6	abstract	new	coref	13-9
9-7	1203-1207	have	_	_	_	_
9-8	1208-1212	been	_	_	_	_
9-9	1213-1224	exclusively	_	_	_	_
9-10	1225-1235	recognized	_	_	_	_
9-11	1236-1238	as	_	_	_	_
9-12	1239-1247	relevant	_	_	_	_
9-13	1248-1250	in	_	_	_	_
9-14	1251-1254	CRC	abstract|substance[82]	giv|new[82]	coref	10-22
9-15	1255-1269	carcinogenesis	substance[82]	new[82]	_	_
9-16	1270-1271	.	_	_	_	_

#Text=As mentioned above , the TRPV1 channel is also involved in IBD , a chronic disorder strongly correlated with risk of CRC .
10-1	1272-1274	As	_	_	_	_
10-2	1275-1284	mentioned	_	_	_	_
10-3	1285-1290	above	_	_	_	_
10-4	1291-1292	,	_	_	_	_
10-5	1293-1296	the	abstract[84]	new[84]	_	_
10-6	1297-1302	TRPV1	abstract|abstract[84]	giv|new[84]	coref	11-9[91_0]
10-7	1303-1310	channel	abstract[84]	new[84]	_	_
10-8	1311-1313	is	_	_	_	_
10-9	1314-1318	also	_	_	_	_
10-10	1319-1327	involved	_	_	_	_
10-11	1328-1330	in	_	_	_	_
10-12	1331-1334	IBD	abstract	new	appos	10-14[86_0]
10-13	1335-1336	,	_	_	_	_
10-14	1337-1338	a	abstract[86]	giv[86]	_	_
10-15	1339-1346	chronic	abstract[86]	giv[86]	_	_
10-16	1347-1355	disorder	abstract[86]	giv[86]	_	_
10-17	1356-1364	strongly	abstract[86]	giv[86]	_	_
10-18	1365-1375	correlated	abstract[86]	giv[86]	_	_
10-19	1376-1380	with	abstract[86]	giv[86]	_	_
10-20	1381-1385	risk	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-21	1386-1388	of	abstract[86]|abstract[87]	giv[86]|new[87]	_	_
10-22	1389-1392	CRC	abstract[86]|abstract[87]|abstract	giv[86]|new[87]|giv	coref	11-14[93_0]
10-23	1393-1394	.	_	_	_	_

#Text=Animal models have demonstrated a protective role for TRPV1 in the tumorigenesis of colon cancer , indeed TRPV1- Knockout mice exhibited lower expression of anti-inflammatory neuropeptides and greater occurrence and number of CRC compared with controls .
11-1	1395-1401	Animal	abstract[89]	new[89]	_	_
11-2	1402-1408	models	abstract[89]	new[89]	_	_
11-3	1409-1413	have	_	_	_	_
11-4	1414-1426	demonstrated	_	_	_	_
11-5	1427-1428	a	abstract[90]	giv[90]	_	_
11-6	1429-1439	protective	abstract[90]	giv[90]	_	_
11-7	1440-1444	role	abstract[90]	giv[90]	_	_
11-8	1445-1448	for	abstract[90]	giv[90]	_	_
11-9	1449-1454	TRPV1	abstract[90]|abstract[91]	giv[90]|giv[91]	coref	12-15[0_91]
11-10	1455-1457	in	abstract[90]|abstract[91]	giv[90]|giv[91]	_	_
11-11	1458-1461	the	abstract[90]|abstract[91]|abstract[92]	giv[90]|giv[91]|giv[92]	_	_
11-12	1462-1475	tumorigenesis	abstract[90]|abstract[91]|abstract[92]	giv[90]|giv[91]|giv[92]	_	_
11-13	1476-1478	of	abstract[90]|abstract[91]|abstract[92]	giv[90]|giv[91]|giv[92]	_	_
11-14	1479-1484	colon	abstract[90]|abstract[91]|abstract[92]|abstract[93]	giv[90]|giv[91]|giv[92]|giv[93]	coref	11-33[0_93]
11-15	1485-1491	cancer	abstract[90]|abstract[91]|abstract[92]|abstract[93]	giv[90]|giv[91]|giv[92]|giv[93]	_	_
11-16	1492-1493	,	_	_	_	_
11-17	1494-1500	indeed	_	_	_	_
11-18	1501-1507	TRPV1-	abstract|animal[96]	new|new[96]	_	_
11-19	1508-1516	Knockout	person|animal[96]	new|new[96]	_	_
11-20	1517-1521	mice	animal[96]	new[96]	_	_
11-21	1522-1531	exhibited	_	_	_	_
11-22	1532-1537	lower	abstract[97]|abstract[98]	giv[97]|giv[98]	_	_
11-23	1538-1548	expression	abstract[97]|abstract[98]	giv[97]|giv[98]	_	_
11-24	1549-1551	of	abstract[97]|abstract[98]	giv[97]|giv[98]	_	_
11-25	1552-1569	anti-inflammatory	abstract[97]|abstract[98]|abstract[99]	giv[97]|giv[98]|new[99]	_	_
11-26	1570-1583	neuropeptides	abstract[97]|abstract[98]|abstract[99]	giv[97]|giv[98]|new[99]	_	_
11-27	1584-1587	and	abstract[98]	giv[98]	_	_
11-28	1588-1595	greater	abstract[98]|event[100]	giv[98]|new[100]	_	_
11-29	1596-1606	occurrence	abstract[98]|event[100]	giv[98]|new[100]	_	_
11-30	1607-1610	and	abstract[98]	giv[98]	_	_
11-31	1611-1617	number	abstract[98]|abstract[101]	giv[98]|new[101]	_	_
11-32	1618-1620	of	abstract[98]|abstract[101]	giv[98]|new[101]	_	_
11-33	1621-1624	CRC	abstract[98]|abstract[101]|abstract	giv[98]|new[101]|giv	coref	12-19
11-34	1625-1633	compared	abstract[98]|abstract[101]	giv[98]|new[101]	_	_
11-35	1634-1638	with	abstract[98]|abstract[101]	giv[98]|new[101]	_	_
11-36	1639-1647	controls	abstract[98]|abstract[101]|event	giv[98]|new[101]|new	_	_
11-37	1648-1649	.	_	_	_	_

#Text=In accordance with these data , Sung and colleagues demonstrated that agonist-mediated activation of TRPV1 induced apoptosis of CRC cells .
12-1	1650-1652	In	_	_	_	_
12-2	1653-1663	accordance	_	_	_	_
12-3	1664-1668	with	_	_	_	_
12-4	1669-1674	these	abstract[104]	new[104]	coref	16-1[146_104]
12-5	1675-1679	data	abstract[104]	new[104]	_	_
12-6	1680-1681	,	_	_	_	_
12-7	1682-1686	Sung	person	new	_	_
12-8	1687-1690	and	_	_	_	_
12-9	1691-1701	colleagues	person	new	_	_
12-10	1702-1714	demonstrated	_	_	_	_
12-11	1715-1719	that	_	_	_	_
12-12	1720-1736	agonist-mediated	event[107]	new[107]	_	_
12-13	1737-1747	activation	event[107]	new[107]	_	_
12-14	1748-1750	of	event[107]	new[107]	_	_
12-15	1751-1756	TRPV1	event[107]|abstract	new[107]|giv	coref	17-11
12-16	1757-1764	induced	_	_	_	_
12-17	1765-1774	apoptosis	event[109]	new[109]	_	_
12-18	1775-1777	of	event[109]	new[109]	_	_
12-19	1778-1781	CRC	event[109]|abstract|object[111]	new[109]|giv|giv[111]	coref|coref	13-13|13-27[121_111]
12-20	1782-1787	cells	event[109]|object[111]	new[109]|giv[111]	_	_
12-21	1788-1789	.	_	_	_	_

#Text=On the other hand , an overexpression of TRPV6 in SW480 colorectal cancer cell lines and colon carcinomas have been associated with an enhanced proliferation of malignant cells .
13-1	1790-1792	On	_	_	_	_
13-2	1793-1796	the	_	_	_	_
13-3	1797-1802	other	_	_	_	_
13-4	1803-1807	hand	_	_	_	_
13-5	1808-1809	,	_	_	_	_
13-6	1810-1812	an	event[112]	new[112]	_	_
13-7	1813-1827	overexpression	event[112]	new[112]	_	_
13-8	1828-1830	of	event[112]	new[112]	_	_
13-9	1831-1836	TRPV6	event[112]|abstract	new[112]|giv	coref	16-6
13-10	1837-1839	in	event[112]	new[112]	_	_
13-11	1840-1845	SW480	event[112]|abstract|object[117]	new[112]|new|new[117]	coref	15-11[141_117]
13-12	1846-1856	colorectal	event[112]|object[117]	new[112]|new[117]	_	_
13-13	1857-1863	cancer	event[112]|abstract|object[117]	new[112]|giv|new[117]	coref	14-40
13-14	1864-1868	cell	event[112]|place|object[117]	new[112]|giv|new[117]	_	_
13-15	1869-1874	lines	event[112]|object[117]	new[112]|new[117]	_	_
13-16	1875-1878	and	event[112]	new[112]	_	_
13-17	1879-1884	colon	event[112]|substance|abstract[119]	new[112]|new|new[119]	_	_
13-18	1885-1895	carcinomas	event[112]|abstract[119]	new[112]|new[119]	_	_
13-19	1896-1900	have	_	_	_	_
13-20	1901-1905	been	_	_	_	_
13-21	1906-1916	associated	_	_	_	_
13-22	1917-1921	with	_	_	_	_
13-23	1922-1924	an	abstract[120]	giv[120]	_	_
13-24	1925-1933	enhanced	abstract[120]	giv[120]	_	_
13-25	1934-1947	proliferation	abstract[120]	giv[120]	_	_
13-26	1948-1950	of	abstract[120]	giv[120]	_	_
13-27	1951-1960	malignant	abstract[120]|object[121]	giv[120]|giv[121]	coref	15-6[139_121]
13-28	1961-1966	cells	abstract[120]|object[121]	giv[120]|giv[121]	_	_
13-29	1967-1968	.	_	_	_	_

#Text=In a recent report , Pérez-Riesgo et al. have assessed differential gene expression of all human TRP channels by Next Generation Sequencing ( NGS ) to investigate differences in expression of several genes involved in intracellular Ca2+ transport in CRC .
14-1	1969-1971	In	_	_	_	_
14-2	1972-1973	a	abstract[122]	new[122]	_	_
14-3	1974-1980	recent	abstract[122]	new[122]	_	_
14-4	1981-1987	report	abstract[122]	new[122]	_	_
14-5	1988-1989	,	_	_	_	_
14-6	1990-2002	Pérez-Riesgo	person	new	_	_
14-7	2003-2005	et	_	_	_	_
14-8	2006-2009	al.	_	_	_	_
14-9	2010-2014	have	_	_	_	_
14-10	2015-2023	assessed	_	_	_	_
14-11	2024-2036	differential	abstract[125]	new[125]	_	_
14-12	2037-2041	gene	abstract|abstract[125]	new|new[125]	_	_
14-13	2042-2052	expression	abstract[125]	new[125]	_	_
14-14	2053-2055	of	abstract[125]	new[125]	_	_
14-15	2056-2059	all	abstract[125]|abstract[127]	new[125]|giv[127]	coref	17-11[161_127]
14-16	2060-2065	human	abstract[125]|abstract[127]	new[125]|giv[127]	_	_
14-17	2066-2069	TRP	abstract[125]|abstract|abstract[127]	new[125]|giv|giv[127]	coref	16-10
14-18	2070-2078	channels	abstract[125]|abstract[127]	new[125]|giv[127]	_	_
14-19	2079-2081	by	_	_	_	_
14-20	2082-2086	Next	abstract[128]|abstract[129]	new[128]|new[129]	appos	14-24[0_129]
14-21	2087-2097	Generation	abstract[128]|abstract[129]	new[128]|new[129]	_	_
14-22	2098-2108	Sequencing	abstract[129]	new[129]	_	_
14-23	2109-2110	(	_	_	_	_
14-24	2111-2114	NGS	abstract	giv	_	_
14-25	2115-2116	)	_	_	_	_
14-26	2117-2119	to	_	_	_	_
14-27	2120-2131	investigate	_	_	_	_
14-28	2132-2143	differences	abstract[131]	giv[131]	_	_
14-29	2144-2146	in	abstract[131]	giv[131]	_	_
14-30	2147-2157	expression	abstract[131]|abstract[132]	giv[131]|new[132]	coref	17-9[158_132]
14-31	2158-2160	of	abstract[131]|abstract[132]	giv[131]|new[132]	_	_
14-32	2161-2168	several	abstract[131]|abstract[132]|abstract[133]	giv[131]|new[132]|new[133]	_	_
14-33	2169-2174	genes	abstract[131]|abstract[132]|abstract[133]	giv[131]|new[132]|new[133]	_	_
14-34	2175-2183	involved	abstract[131]|abstract[132]|abstract[133]	giv[131]|new[132]|new[133]	_	_
14-35	2184-2186	in	abstract[131]|abstract[132]|abstract[133]	giv[131]|new[132]|new[133]	_	_
14-36	2187-2200	intracellular	abstract[131]|abstract[132]|abstract[133]|abstract[135]	giv[131]|new[132]|new[133]|new[135]	_	_
14-37	2201-2205	Ca2+	abstract[131]|abstract[132]|abstract[133]|substance|abstract[135]	giv[131]|new[132]|new[133]|new|new[135]	_	_
14-38	2206-2215	transport	abstract[131]|abstract[132]|abstract[133]|abstract[135]	giv[131]|new[132]|new[133]|new[135]	_	_
14-39	2216-2218	in	abstract[131]|abstract[132]|abstract[133]	giv[131]|new[132]|new[133]	_	_
14-40	2219-2222	CRC	abstract[131]|abstract[132]|abstract[133]|abstract	giv[131]|new[132]|new[133]|giv	coref	15-12[140_0]
14-41	2223-2224	.	_	_	_	_

#Text=The results obtained , comparing human normal colonic cells versus human colon cancer lines , revealed that only a dozen of the TRPs are expressed in colonic cells , either normal or tumor .
15-1	2225-2228	The	abstract[137]	new[137]	_	_
15-2	2229-2236	results	abstract[137]	new[137]	_	_
15-3	2237-2245	obtained	abstract[137]	new[137]	_	_
15-4	2246-2247	,	abstract[137]	new[137]	_	_
15-5	2248-2257	comparing	abstract[137]	new[137]	_	_
15-6	2258-2263	human	abstract[137]|object[139]	new[137]|giv[139]	coref	15-27[144_139]
15-7	2264-2270	normal	abstract[137]|object[139]	new[137]|giv[139]	_	_
15-8	2271-2278	colonic	abstract[137]|abstract|object[139]	new[137]|new|giv[139]	_	_
15-9	2279-2284	cells	abstract[137]|object[139]	new[137]|giv[139]	_	_
15-10	2285-2291	versus	abstract[137]|object[139]	new[137]|giv[139]	_	_
15-11	2292-2297	human	abstract[137]|object[139]|object[141]	new[137]|giv[139]|giv[141]	_	_
15-12	2298-2303	colon	abstract[137]|object[139]|abstract[140]|object[141]	new[137]|giv[139]|giv[140]|giv[141]	coref	16-15[0_140]
15-13	2304-2310	cancer	abstract[137]|object[139]|abstract[140]|object[141]	new[137]|giv[139]|giv[140]|giv[141]	_	_
15-14	2311-2316	lines	abstract[137]|object[139]|object[141]	new[137]|giv[139]|giv[141]	_	_
15-15	2317-2318	,	_	_	_	_
15-16	2319-2327	revealed	_	_	_	_
15-17	2328-2332	that	_	_	_	_
15-18	2333-2337	only	object[142]	new[142]	_	_
15-19	2338-2339	a	object[142]	new[142]	_	_
15-20	2340-2345	dozen	object[142]	new[142]	_	_
15-21	2346-2348	of	object[142]	new[142]	_	_
15-22	2349-2352	the	object[142]|abstract[143]	new[142]|giv[143]	_	_
15-23	2353-2357	TRPs	object[142]|abstract[143]	new[142]|giv[143]	_	_
15-24	2358-2361	are	_	_	_	_
15-25	2362-2371	expressed	_	_	_	_
15-26	2372-2374	in	_	_	_	_
15-27	2375-2382	colonic	object[144]	giv[144]	coref	16-15[151_144]
15-28	2383-2388	cells	object[144]	giv[144]	_	_
15-29	2389-2390	,	_	_	_	_
15-30	2391-2397	either	_	_	_	_
15-31	2398-2404	normal	_	_	_	_
15-32	2405-2407	or	_	_	_	_
15-33	2408-2413	tumor	abstract	giv	_	_
15-34	2414-2415	.	_	_	_	_

#Text=The data also indicated that TRPV6 was the unique TRP gene significantly overexpressed in CRC cells , resembling the previously reported enhanced levels of TRPV6 in prostate cancer .
16-1	2416-2419	The	abstract[146]	giv[146]	_	_
16-2	2420-2424	data	abstract[146]	giv[146]	_	_
16-3	2425-2429	also	_	_	_	_
16-4	2430-2439	indicated	_	_	_	_
16-5	2440-2444	that	_	_	_	_
16-6	2445-2450	TRPV6	abstract	giv	coref	16-8[149_0]
16-7	2451-2454	was	_	_	_	_
16-8	2455-2458	the	abstract[149]	giv[149]	coref	16-25[0_149]
16-9	2459-2465	unique	abstract[149]	giv[149]	_	_
16-10	2466-2469	TRP	abstract|abstract[149]	giv|giv[149]	_	_
16-11	2470-2474	gene	abstract[149]	giv[149]	_	_
16-12	2475-2488	significantly	abstract[149]	giv[149]	_	_
16-13	2489-2502	overexpressed	abstract[149]	giv[149]	_	_
16-14	2503-2505	in	abstract[149]	giv[149]	_	_
16-15	2506-2509	CRC	abstract[149]|abstract|object[151]	giv[149]|giv|giv[151]	coref	16-27[155_0]
16-16	2510-2515	cells	abstract[149]|object[151]	giv[149]|giv[151]	_	_
16-17	2516-2517	,	abstract[149]	giv[149]	_	_
16-18	2518-2528	resembling	abstract[149]	giv[149]	_	_
16-19	2529-2532	the	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-20	2533-2543	previously	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-21	2544-2552	reported	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-22	2553-2561	enhanced	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-23	2562-2568	levels	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-24	2569-2571	of	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-25	2572-2577	TRPV6	abstract[149]|abstract[152]|abstract	giv[149]|new[152]|giv	coref	17-13
16-26	2578-2580	in	abstract[149]|abstract[152]	giv[149]|new[152]	_	_
16-27	2581-2589	prostate	abstract[149]|abstract[152]|object|abstract[155]	giv[149]|new[152]|giv|giv[155]	coref	17-16[0_155]
16-28	2590-2596	cancer	abstract[149]|abstract[152]|abstract[155]	giv[149]|new[152]|giv[155]	_	_
16-29	2597-2598	.	_	_	_	_

#Text=Notwithstanding , the functional consequences of changes in expression of TRPV1 and TRPV6 channels in CRC remain to be established .
17-1	2599-2614	Notwithstanding	_	_	_	_
17-2	2615-2616	,	_	_	_	_
17-3	2617-2620	the	abstract[156]	new[156]	_	_
17-4	2621-2631	functional	abstract[156]	new[156]	_	_
17-5	2632-2644	consequences	abstract[156]	new[156]	_	_
17-6	2645-2647	of	abstract[156]	new[156]	_	_
17-7	2648-2655	changes	abstract[156]|event[157]	new[156]|new[157]	_	_
17-8	2656-2658	in	abstract[156]|event[157]	new[156]|new[157]	_	_
17-9	2659-2669	expression	abstract[156]|event[157]|abstract[158]	new[156]|new[157]|giv[158]	_	_
17-10	2670-2672	of	abstract[156]|event[157]|abstract[158]	new[156]|new[157]|giv[158]	_	_
17-11	2673-2678	TRPV1	abstract[156]|event[157]|abstract[158]|abstract|abstract[161]	new[156]|new[157]|giv[158]|giv|giv[161]	_	_
17-12	2679-2682	and	abstract[156]|event[157]|abstract[158]|abstract[161]	new[156]|new[157]|giv[158]|giv[161]	_	_
17-13	2683-2688	TRPV6	abstract[156]|event[157]|abstract[158]|abstract|abstract[161]	new[156]|new[157]|giv[158]|giv|giv[161]	_	_
17-14	2689-2697	channels	abstract[156]|event[157]|abstract[158]|abstract[161]	new[156]|new[157]|giv[158]|giv[161]	_	_
17-15	2698-2700	in	abstract[156]|event[157]|abstract[158]	new[156]|new[157]|giv[158]	_	_
17-16	2701-2704	CRC	abstract[156]|event[157]|abstract[158]|abstract	new[156]|new[157]|giv[158]|giv	_	_
17-17	2705-2711	remain	_	_	_	_
17-18	2712-2714	to	_	_	_	_
17-19	2715-2717	be	_	_	_	_
17-20	2718-2729	established	_	_	_	_
17-21	2730-2731	.	_	_	_	_
